Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597753 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
A Phase 3 study of Chronic Kidney Disease and Anemia, sponsored by Affymax.
- Completed
- Registry status
- Phase 3
- Development phase
- 803
- Enrollment target
- 20
- Study locations
NCT00597753 is a Phase 3 study of Chronic Kidney Disease and Anemia that has completed, run by Affymax. The registered enrollment target is 803 participants, below the 3,199-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00597753, a Phase 3 study of Chronic Kidney Disease and Anemia, has completed, sponsored by Affymax.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 803 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
Conditions Studied
Interventions
- DRUG Epoetin Alfa
- DRUG peginesatide
Study Locations (20)
California
- Research Facility - Fairfield
- Research Facility - Granada Hills
- Research Facility - Los Alamitos
- Research Facility - Los Angeles
- Research Facility - Los Angeles
- Research Facility - Los Angeles
- Research Facility - Lynwood
- Research Facility - Monterey Park
- Research Facility - Mountain View
- Research Facility - Paramount
- Research Facilities (2) - San Diego
- Research Facility - San Dimas
- Research Facility - Whittier
Florida
- Research Facility - Hudson
- Research Facility - Ocala
- Research Facility - Orlando
- Research Facility - Orlando
Arkansas
- Research Facility - Paragould
Colorado
- Research Facility - Denver
Connecticut
- Research Facility - Middlebury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00597753
The ClinicalTrials.gov registry entry for NCT00597753 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 803 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,199-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (75% lower). The listed sponsor is Affymax, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Epoetin Alfa is the first listed.
NCT00597753 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00597753 about?
NCT00597753 is a clinical study titled "Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis". The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.
What is the current status of trial NCT00597753?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 803 participants. The study started on 2007-09. Estimated completion is 2010-01.
What conditions does trial NCT00597753 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Anemia, Chronic Renal Failure.
What interventions are being tested in trial NCT00597753?
The interventions under investigation include: Epoetin Alfa (DRUG), peginesatide (DRUG).
Who is sponsoring clinical trial NCT00597753?
This trial is sponsored by Affymax, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00597753 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.